Development of polypoidal lesions in age-related macular degeneration.
OBJECTIVE
To investigate the development of polypoidal lesions using indocyanine green angiography (IA) in eyes with typical age-related macular degeneration (AMD).


METHODS
We retrospectively reviewed the medical records of 47 consecutive patients (47 eyes) with typical AMD who had been followed up with IA for at least 2 years.


RESULTS
At the initial visit, although all eyes showed classic and/or occult choroidal neovascularization (CNV) associated with AMD, no eyes showed polypoidal lesions by IA. However, during follow-up, 13 (27.7%) of the 47 eyes did show polypoidal lesions. All polypoidal lesions developed at the edge of persistent CNV or, more often, at the terminus of recently progressed CNV. Of 12 eyes with a final lesion area >8 disc area, 7 (58.3%) showed newly developed polypoidal lesions. In the eyes with these newly developed polypoidal lesions, the mean area of the vascular lesion had extended significantly from 10.50 ± 7.88 mm² to 20.87 ± 10.21 mm² during follow-up (P=0.0018).


CONCLUSIONS
The current observation suggests that IA of active AMD sometimes reveals polypoidal lesions if there is progression of the CNV in the subretinal pigment epithelium space.
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. tujikawa@kuhp.kyoto-u.ac.jp
A
A
Tsujikawa
Y
Y
Ojima
K
K
Yamashiro
S
S
Ooto
H
H
Tamura
I
I
Nakata
N
N
Yoshimura
D000368:Aged; D000369:Aged, 80 and over; D002829:Choroid / Q000098:blood supply*; D020256:Choroidal Neovascularization / Q000150:complications / Q000473:pathology*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007208:Indocyanine Green; D008268:Macular Degeneration / Q000150:complications / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011127:Polyps / Q000209:etiology / Q000473:pathology*; D012189:Retrospective Studies
D007208:Indocyanine Green
Jpn J Ophthalmol. 2010 Jul;54(4):310-9
20700799
Arch Ophthalmol. 2003 Oct;121(10):1392-6
14557174
Ophthalmology. 1992 Feb;99(2):287-91
1553221
Am J Ophthalmol. 2007 Jul;144(1):15-22
17509509
Graefes Arch Clin Exp Ophthalmol. 2002 May;240(5):354-61
12073058
N Engl J Med. 2006 Oct 5;355(14):1432-44
17021319
Retina. 2009 Nov-Dec;29(10):1522-6
19898184
Arch Ophthalmol. 1997 Apr;115(4):478-85
9109756
Retina. 1990;10(1):9-17
2343198
Arch Ophthalmol. 1999 Aug;117(8):1035-42
10448746
Surv Ophthalmol. 2004 Jan-Feb;49(1):25-37
14711438
Am J Ophthalmol. 2010 Nov;150(5):666-73
20719300
N Engl J Med. 2006 Oct 5;355(14):1419-31
17021318
Nippon Ganka Gakkai Zasshi. 1999 Jul;103(7):527-37
10443127
Br J Ophthalmol. 2008 May;92(5):661-6
18356265
Am J Ophthalmol. 2009 Jun;147(6):1037-41, 1041.e1-2
19268887
Eye (Lond). 2010 Mar;24(3):483-90
20075967
Ophthalmology. 1998 Aug;105(8):1380-5
9709746
Retina. 1992;12(3):191-223
1384094
Ophthalmology. 2010 Aug;117(8):1567-70
20378180
Am J Ophthalmol. 1985 Oct 15;100(4):560-9
2413762
Retina. 1990;10(1):1-8
1693009
Br J Ophthalmol. 2008 Jan;92(1):70-3
17567661
Am J Ophthalmol. 2009 Jul;148(1):70-8.e1
19403115
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1101-5
18326737
Arch Ophthalmol. 1991 Sep;109(9):1242-57
1718252
Retina. 2000;20(6):650-4
11131419
Retina. 1995;15(2):100-10
7542796
Acta Ophthalmol. 2010 Jun;88(4):e107-14
20337601
Korean J Ophthalmol. 2008 Jun;22(2):92-9
18612226
Ophthalmology. 2010 May;117(5):928-38
20132989
Arch Ophthalmol. 1999 Nov;117(11):1503-10
10565519
Am J Ophthalmol. 2007 Jul;144(1):7-14
17467649
Br J Ophthalmol. 2010 Mar;94(3):297-301
19726427
Am J Ophthalmol. 2002 May;133(5):639-48
11992861
Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1286-90
9620093
Eur J Ophthalmol. 1992 Jul-Sep;2(3):115-21
1280499
Br J Ophthalmol. 2002 Mar;86(3):321-7
11864892
Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2613-9
18515590
Am J Ophthalmol. 2007 Oct;144(4):608-12
17692272
Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):491-9
17917739